Research Article
Safety of Intravenous Immunoglobulin (Tegeline®), Administered at Home in Patients with Autoimmune Disease: Results of a French Study
Table 3
Definition of patients’ profile who could benefit from home-based intravenous immunoglobulin (Tegeline) by the investigators (safety population,
).
| | Total number of responses of investigators (%) |
| Good understanding of patient on the advantages and inconveniences of home-based IVIg | 82.6 | Absence of acute renal failure | 82.6 | Autoimmune disease well diagnosed and requiring administration of regular IVIg | 80.4 | Good safety of Tegeline at the hospital (during the 3 last consecutive cycles at the hospital before starting treatment at home) | 78.3 | Choice of patient | 76.1 | Absence of chronic renal failure | 76.1 | Minimum number of IVIg cycles realized at the hospital considered necessary, before starting treatment at home | 76.1 | Collaboration with a service provider, one visiting nurse, or home hospitalization | 69.6 | No venous problem | 69.6 | Prescription of Tegeline by a hospital doctor | 65.2 | Minimum/maximum rate of flow considered necessary for the hospital, before the administration of Tegeline at home | 45.7 | Absence of thrombosis in veins for the Tegeline infusion | 39.1 | Presence of a third person at home | 15.2 | Well-balanced hypertension | 10.9 | Well-balanced cardiopathy | 8.7 | Collaboration with a home-hospitalization service provider | 6.5 | Well-balanced diabetes | 4.3 | Well-balanced coronary insufficiency | 4.3 |
|
|